Trial Profile
A randomized, double-blind, placebo-controlled, 3-way cross-over study to evaluate the effects of APD125 in patients with chronic primary insomnia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Nelotanserin (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Arena Pharmaceuticals
- 12 Jun 2008 Positive results has been presented in an oral presentation at SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies according to an Arena Pharmaceuticals media release.
- 07 Sep 2007 Status changed from recruiting to completed.
- 06 Mar 2007 Status changed from planning to recruiting